B. pertussis vaccine production using carbodiimides
AssigneeThe University Court of the University of Glasgow
InventorsRoger Parton, Duncan E. S. Stewart-Tull
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of preparing a substantially non-toxic immunogenic preparation of pertussis toxic comprising treatment of pertussis toxin with a carbodiimide. The preparation may be used for vaccination against whooping cough as well as making vaccines for use in immunization against whooping cough. Desirably the pertussis toxin is treated in the form of an intimate admixture with filamentous.
Claims14
A method of preparing a substantially non-toxic immunogenic preparation of pertussis toxin comprising treatment of pertussis toxin with a carbodiimide, said pertussis toxin being in the form of an intimate admixture with filamentous haemagglutinin.
A method of preparing a substantiallly non-toxic immunogenic preparation suitable for use in vaccination against B.pertussis which method comprises treatment of pertussis toxin in intimate admixture with filamentous haemagglutinin, with an effective toxoiding amount of a carbodiimide.
A process for the production of B. pertussis vaccine comprising the steps of:
- culturing B. pertussis cells in a culture medium;
- allowing said cells to release haemagglutinin (FHA) and pertussis toxin (PT) antigens into said culture medium;
- recovering said FHA and PT antigens together from said culture medium substantially free of cells and endotoxin;
- treating said FHA and PT antigens together, with a water-soluble carbodiimide so as to detoxify them substantially;
- and
- formulating the detoxified PT and FHA in a physiologically acceptable carrier.
Dependencies are inferred from the claim text.